A randomised, double blind, placebo-controlled pilot trial studying the effects of Lactobacillus reuteri ATCC 55730 on the incidence of diarrhoea in hospitalised adults treated with different antibiotics.
The patients ingested either Lactobacillus reuteri 2×10^8 CFU (one tablet twice daily, n=13) or an identical placebo (n=10) for 4 weeks. Pneumonia, abscess, chronic obstructive pulmonary disease and bronchitis were the most common diagnoses that required antibiotic treatment. Stool frequency, consistency and gastrointestinal symptoms were monitored during the 4 weeks and for a further 2 weeks after the supplementation was stopped.
The patients given Lactobacillus reuteri had a significantly lower incidence of diarrhoea compared to those given placebo: 7.7% in the probiotic group vs. 50.0% in the placebo group (p=0.02). There were no differences in the incidence or severity of nausea, vomiting, abdominal cramping, bloating, gas, constipation
Conclusion: The intake of Lactobacillus reuteri significantly decreased the incidence of antibiotic-associated diarrhoea in hospitalised adults, and Lactobacillus reuteri was well tolerated.